Countries China
China Approves Sarclisa as First Anti-CD38 Therapy for Newly Diagnosed Multiple Myeloma Patients
Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant A...
January 31, 2025 | News
Advanced Aesthetic Technologies Secures Regulatory Approval for Algeness® VL Dermal Filler in China
Advanced Aesthetic Technologies, Inc. (“AAT”) announced today that its partner in China, Lanzhou Biotechnique Development Co., Ltd. ("LanDev"),...
January 30, 2025 | News
Akeso Secures CDE Approval for IL-17 Monoclonal Antibody Gumokimab to Address Plaque Psoriasis
Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the New Drug Application (NDA) of its internally-developed IL-17-targeting mon...
January 27, 2025 | News
Kelun-Biotech Secures NMPA Approval for Tagitanlimab in First-Line Treatment of Nasopharyngeal Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company received marketing authorization in China from Natio...
January 24, 2025 | News
Shandong Cancer Hospital Treats 100 Patients with Accuray’s Tomo® C System, Advancing Precision Radiotherapy in China
Accuray Incorporated announced that Shandong Cancer Hospital and Institute has achieved a milestone with the completion of treatment for 100 patients ...
January 24, 2025 | News
AIIB Launches Inaugural Health Strategy to Strengthen Resilient Health Systems Across Asia
The Asian Infrastructure Investment Bank (AIIB) launched its inaugural health strategy in December 2024, marking its first comprehensive str...
January 23, 2025 | News
InnoCare Pharma, KeyMed Biosciences, and Prolium Bioscience Partner on $520M Global Licensing Deal for CD20xCD3 Bispecific Antibody
InnoCare Pharma and KeyMed Biosciences announced that the two companies, together with their joint venture, have jointly entered into an exclusive li...
January 21, 2025 | News
CARsgen Therapeutics Administers First Dose of KJ-C2320 Allogeneic CAR T-Cell Therapy in Investigator-Initiated Trial
CARsgen Therapeutics Holdings Limited , a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors...
January 21, 2025 | News
YolTech Therapeutics Launches Clinical Trial for YOLT-204 a First-in-Class Gene Editing Therapy for Beta-Thalassemia
YolTech Therapeutics, a clinical-stage gene editing company dedicated to delivering lifelong cures, announced the initiation of a clinical trial for Y...
January 21, 2025 | News
Innovent and ASK Pharm Secure NMPA Approval for Limertinib in EGFR T790M-Mutated NSCLC
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality me...
January 20, 2025 | News
Zai Lab’s KarXT NDA Accepted by China’s NMPA for Schizophrenia Treatment
Zai Lab Limited announced that China’s National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for KarXT for the ...
January 20, 2025 | News
Guangzhou Fermion Partners with Simcere to Advance Clinical-Stage SSTR4 Agonist for Pain Management
Guangzhou Fermion Technology Co., Ltd. and Simcere Pharmaceutical Group Limited have announced a partnership to develop a clinical-stage pain treatment ass...
January 20, 2025 | News
Innovent and ASK Pharm Secure NMPA Approval for Limertinib to Treat EGFR T790M-Mutated NSCLC
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality me...
January 17, 2025 | News
IMPACT Therapeutics’ Senaparib Gains NMPA Approval as First-Line Maintenance Therapy for Advanced Ovarian Cancer
IMPACT Therapeutics ("IMPACT"), a biopharmaceutical company focusing on the discovery and development of targeted anti-cancer therapeutics based on synthet...
January 17, 2025 | News
Most Read
- 2025 Pharma and Medical Device Trends for Manufacturing Leaders
- 25 High-Value Drugs Losing Patent Protection in 2025: What It Means for Healthcare
- BioPharma Trends 2025: 25 Key Insights Shaping Asia Pacific's Future
- Driving Oncology Forward: 25 Companies Redefining Antibody-Drug Conjugates (ADCs) in 2025
- 25 Biopharma Leaders Shaping a Sustainable 2025: Innovation Meets Environmental Responsibility
- 25 Leading AI Companies to Watch in 2025: Transforming Drug Discovery and Precision Medicine
- Mr. Brendan O’Callaghan Discusses Sanofi’s Singapore Modulus Facility: Advancing Biopharma Manufacturing and Pandemic Preparedness
- Shaping the Future of PCV Care: Insights from Roche’s Stefan Scheidl on the SALWEEN Trial
- Pam Cheng Outlines AstraZeneca’s Bold Vision for Singapore’s First End-to-End ADC Manufacturing Facility
- Shaping a Health Innovation Hub: Alessandro Falcone Reflects on JLABS Singapore’s Milestone Year and Future Goals
Bio Jobs
- Top Management Shakeups of 2024: Redefining Pharma, Biopharma, and Biotech Leadership
- James Park Joins South Korean LOTTE BIOLOGICS as New CEO to Lead Global Expansion
- Australia Takes the Lead: Moderna Opens Southern Hemisphere’s First mRNA Manufacturing Facility in Victoria
- Eli Lilly Announces $3 Billion Expansion in Wisconsin to Boost Global Medicine Production
- Ngee Ann Polytechnic Partners with Merck Singapore to Elevate Biopharmaceutical Education
- Pam Cheng Outlines AstraZeneca’s Bold Vision for Singapore’s First End-to-End ADC Manufacturing Facility
- Life Sciences CEOs Bet Big on AI and Workforce Growth Despite Economic and Industry Headwinds
News
